Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 4, No. 2, 2012
Issue release date: May – August
Section title: Published: May 2012

Open Access Gateway

Case Rep Neurol 2012;4:92–96

Childhood Stiff-Person Syndrome Improved with Rituximab

Fekete R. · Jankovic J.
Parkinson’s Disease Center and Movement Disorders Clinic,Department of Neurology, Baylor College of Medicine, Houston, Tex., USA
email Corresponding Author

Assist. Prof. Robert Fekete, MD

Department of Neurology, Munger Pavilion – 4th Floor

40 Sunshine Cottage Road

Valhalla, New York 10595 (USA)

Tel. +1 914 594 4293, E-Mail robertfekete@hotmail.com

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Introduction: Stiff-person syndrome (SPS) is manifested by fluctuating rigidity of axial musculature with painful episodic spasms due to simultaneous co-contraction of agonist and antagonist muscles. We present a case report and video illustrating response to treatment with rituximab. Materials and Methods: Case description and video are provided. A literature search for other reports of treatment with rituximab was performed. Results: Nine cases in addition to our case were described. Substantial clinical benefit was reported in 7/9 (78%) cases. Four out of 9 (44%) cases displayed persistent anti-glutamic acid decarboxylase (GAD) antibody positivity. Conclusion: Rituximab is an important treatment strategy in SPS. The persistence of anti-GAD antibody positivity even with clinical remission remains to be elucidated.

© 2012 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: May 2012

Published online: May 31, 2012
Issue release date: May – August

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: (Print)
eISSN: 1662-680X (Online)

For additional information: http://www.karger.com/CRN

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.